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Background: Some investigators have proposed an associa-
tion between certain Chlamydia trachomatis serovars and the
clinical course of infection in humans. A recent study of over
1100 patients with culture confirmed and serotyped
C trachomatis urogenital infection detected no such associa-
tion.
Aims: To corroborate these results using a murine model of
female genital tract infection.
Methods: Various parameters of infection were assessed in
mice intravaginally infected with human genital isolates of
C trachomatis serovar E from four cases with either a clear
symptomatic or asymptomatic clinical course in both the
patient and their partner.
Results: No differences were seen among the strains in the
incidence or duration of infection, polymorphonuclear
granulocyte responses, or upper genital tract progression.
Conclusions: An investigation to determine the correlation
between the clinical manifestations of different isolates of
C trachomatis serovar E in humans and certain parameters of
microbial pathogenesis in a mouse model failed to reveal an
association between the measured parameters and the
tendency of serovar E to produce symptomatic versus
asymptomatic infections in humans. These findings suggest
that differences in the clinical course of infection in humans
seen with these strains may be more related to host factors
than to genetic variation among strains.
S
ome studies have shown an association of certain
Chlamydia trachomatis serovars with specific clinical
symptoms and upper genital tract progression, whereas
others have found no such association. These conflicting
results are partially the result of small study groups,
potentially confounding factors, and inconsistent clinical
characterisation. Recently, a very large study provided
evidence that the role of specific serovars in defined clinical
outcomes may be limited. Geisler et al studied over 1100
patients with culture confirmed and serotyped C trachomatis
infection and concluded that there was no association
between clinical manifestations and the infecting serovar.1
‘‘Some studies have shown an association of certain
Chlamydia trachomatis serovars with specific clinical
symptoms and upper genital tract progression, whereas
others have found no such association’’
Analysis of the course of infection in an animal model
using clinically well characterised human isolates might be
helpful in addressing this issue, by allowing the controlled
assessment of the role of host versus pathogen factors that
influence the course of genital tract infection. Therefore,
using a murine model of female genital tract infection that
can reproducibly distinguish between different human
isolates,2 we investigated the course of C trachomatis infection
in mice using four serovar E isolates from cases in which a
clear symptomatic or clear asymptomatic course was
observed in both the index patients and their partners. The
incidence and duration of infection, the polymorphonuclear
granulocyte (PMN) response, and upper genital tract
progression were assessed after lower genital tract infection.
MATERIAL AND METHODS
Bacterial strains and culture
Four C trachomatis serovar E strains isolated from female
patients with either a clear symptomatic (S1, S2) or
asymptomatic (AS1, AS2) clinical course in both the patient
and their partner3 (table 1) were propagated, titrated, and
isolated in cyclohexamide treated HeLa cell monolayers using
standard techniques.
Murine model, inoculation, and specimen collection
Using a standard model of female genital tract infection,4 5
four groups of 12 progesterone pretreated CF-1 female mice
were inoculated intravaginally by direct instillation of 10 ml
of bacterial suspension containing approximately 16 105
inclusion forming units. Four mice from each strain were
euthanised at day 14, the remaining mice at day 56. Eight
mice served as non-infected controls. Lower genital tract
specimens were obtained by swabbing the vaginal vault and
ectocervix with a calcium alginate swab every two to seven
days up until day 56. Swabs were placed in transport medium
(2-SP) and immediately tested for PMN content before being
frozen. Genital tract tissues and local lymph nodes were
aseptically isolated, divided into specimens, and stored in
2-SP for culture and polymerase chain reaction (PCR)
analysis. All specimens were frozen at 270 C˚ until tested.
Culture, PCR, and PMN responses
The presence of C trachomatis in both the material obtained by
swabbing the lower genital tract, and the thawed, homo-
genised, and centrifugation clarified supernatants from the
upper genital tract was determined using previously
described culture and PCR techniques.3 5 6 Finally, lower
genital tract inflammation was monitored during the first
two weeks of infection by assaying for PMN associated
Abbreviations: IL, interleukin; PCR, polymerase chain reaction; PMN,
polymorphonuclear granulocyte
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esterase activity (MultistixH 2 reagent strips; Bayer
Corporation, Diagnostic Division, Elkhart, Indiana, USA).
STATISTICAL ANALYSIS
Duration of infection data were analysed using the Wilcoxon
rank sum test and the frequency data by x2 or Fisher exact
tests where appropriate.
RESULTS
Lower genital tract infection
No significant differences were noted in the incidence or
duration of infection either among strains or between the
symptomatic and asymptomatic C trachomatis serovar E
isolates (table 2). All culture positive samples were also
PCR positive, and PCR detected additional positive speci-
mens, both for culture negative time points between two
culture positive time points (n = 14) and after the last
culture positive time points (n = 28). All samples were both
culture and PCR negative by day 56. PMN responses in the
lower genital tract were also not significantly different either
between strains within each group or between the combined
data for each group (table 2).
Upper genital tract infection
Progression of the infection into the upper cervix and uterine
horns was detected both by culture and, at greater frequency,
by PCR, but no differences were noted at day 14 between
mice infected with C trachomatis from either symptomatically
or asymptomatically infected women, and no signs of gross
pathology were visible. All upper genital tract material was
negative for C trachomatis on day 56, which was also the case
for all lymph nodes and ovaries from both time points. All
control mice were negative for C trachomatis by either PCR or
culture.
DISCUSSION
Using a well established murine model of C trachomatis
female genital tract infection, we showed that there were no
differences in the incidence and duration of infection, the
lower genital tract PMN response, or the upper genital tract
progression, after lower genital tract infection with clinical
serovar E isolates from female patients with either a clear
symptomatic or asymptomatic course of infection. These
experimental data are in agreement with the findings from
the most recent human epidemiological study of Geisler et al,1
suggesting that, at least within a given oculogenital serovar,
genetic variation among strains may not strongly contribute
to the course of infection. However, it is important to note
that our study was not intended specifically to identify
possible host or chlamydial factors that might contribute to
diverse clinical outcomes. Of interest within the context of
our report are the possible roles that newly described
polymorphisms within the chlamydial plasticity zone, such
as those described in the tryptophan synthase operon,7 might
play a role in subtle host–pathogen interactions that affect
the course of infection, in addition to the stable pattern of
serovar prevalence that exists worldwide among clinical
oculogenital isolates.
‘‘It seems reasonable to suggest that the focus of future
studies to elucidate the basis for differences in clinical
course should include analyses of host genetic factors’’
Although our study was limited to a single serovar, serovar
E is the most prevalent one isolated from genital tract
infections, and the lack of variation in the course of infection
among these four strains in the murine model suggests that
the bacterial background may not have played an important
role in the observed clinical differences in the women from
Table 1 Clinical characteristics associated with Chlamydia trachomatis serovar E isolates
Strain
Self reported complaints Clinical signs of infection
Dysuria Abn Vag Dis Discharge LAP Discharge* Leucocytes
Men/Women Women Men Women Men/Women Men/Women
S1 +/2 + + + m/mp 10/9
S2 +/2 + + + p/mp 10/9
AS1 2/2 2 2 2 2/2 10/0
AS2 2/2 2 2 2 2/m 10/9
*Discharge: 2, none; m, mucous; mp, mucopurulent; p, purulent; leucocytes, number of leucocytes/field, 0–10 or
.10.
Abn Vag Dis, abnormal vaginal discharge; LAP, lower abdominal pain.
Table 2 Comparative summary of course of murine genital tract infection with different clinically characterised Chlamydia
trachomatis serovar E isolates
Strain
Incidence of
infection*
Median duration
of infection
Vaginal PMN content during the acute
phase of infection`
Upper genital tract infection1
Upper cervix Uterine horns
Ovaries
and tubesNeg Trace +/++
S1 6/8 31.5 22% 58% 20% 3/4 2/4 0/4
S2 6/8 31.5 20% 62% 18% 2/4 3/4 0/4
Combined 12/16 31.5 21% 60% 19% 5/8 5/8 0/8
AS1 8/8 35 15% 60% 25% 2/4 3/4 0/4
AS2 5/8 35 20% 55% 25% 2/4 2/4 0/4
Combined 13/16 35 18% 57% 25% 4/8 5/8 0/8
No significant differences were obtained for the parameters evaluated.
*An animal was considered infected if one or more vaginal samples was positive either by culture or PCR; the duration of infection for a given animal was
assigned as the last positive vaginal sample, with the median duration determined from only the infected animals in a group; `PMN responses were determined
during the first two weeks of infection as instructed by the manufacturer; the percentage of the total number of specimens tested during this period within each
category of response is shown; 1a tissue was considered infected if positive either by culture or PCR.
PCR, polymerase chain reaction; PMN, polymorphonuclear granulocytes.
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whom these strains were isolated. Thus, it seems reasonable
to suggest that the focus of future studies to elucidate the
basis for differences in clinical course should include analyses
of host genetic factors. The study of the host genetic
background in relation to disease and infection, called
immunogenetics, is a new and rapidly developing field. By
determining immune mediators that are important in the
susceptibility to infection and the severity of subsequent
disease, the assessment of functional mutations in the
corresponding genes will potentially lead to the identification
of the relevant host factors that contribute to an increased
risk for severe disease. For C trachomatis infections important
mediators such as interferon c, interleukin 12 (IL-12), IL-10,
and tumour necrosis factor a have been identified using
knockout mouse strains and antibody depletion techniques.
Based on these and related findings, studies have already
been conducted that link an increased risk of pelvic
inflammatory disease and tubal infertility with functional
polymorphisms in the IL-10 gene and with certain major
histocompatibility complex class I alleles and HLA types,8 9
and studies are in progress to determine the possible role of
interferon c, IL-12, and the lipopolysaccharide and heat
shock protein responsive Toll-like receptor 410 in susceptibility
to and severity of C trachomatis genital tract infection.
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Take home messages
N Specific Chlamydia trachomatis serovars, which are
based on the omp1 gene encoding the major outer
membrane protein, have been suggested to be
associated with specific clinical manifestations in
humans
N Using a murine model of female genital tract infection,
no difference was seen in the course of infection among
human genital isolates of the most prevalent
C trachomatis serovar associated with human genital
tract disease (serovar E) obtained from cases with
either a clear symptomatic or asymptomatic clinical
course in both women and their partners
N Because the serovar determining genetic background
of oculogenital serovars of C trachomatis may not play
an important role in the course of infection, future
studies should also be directed at an analysis of host
genetic factors that might influence the course of
infection; that is, immunogenetic approaches
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